General Information of Drug (ID: DMLI5VG)

Drug Name
CAR-T cells targeting HER2 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMLI5VG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [3]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [4]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [5]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [6]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [7]
Margetuximab DMKEY6S HER2-positive breast cancer 2C60-2C65 Approved [8]
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [9]
Tucatinib DMBESUA HER2-positive breast cancer 2C60-2C65 Approved [10]
Pertuzumab DMHJV0X Adrenal gland neoplasm Approved [11]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [12]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [3]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [4]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [5]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [6]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [7]
Margetuximab DMKEY6S HER2-positive breast cancer 2C60-2C65 Approved [8]
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [9]
Tucatinib DMBESUA HER2-positive breast cancer 2C60-2C65 Approved [10]
Pertuzumab DMHJV0X Adrenal gland neoplasm Approved [11]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [12]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
2 ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
3 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
5 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
11 Clinical pipeline report, company report or official report of Roche (2009).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.